报价延迟最少15分钟:2025/07/20 15:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.46 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.05/-2.20
|
|
企业价值
223.21M
|
| 资产负债 |
|
每股账面净值
2.89
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
20.22M
|
|
每股收益
2.41
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 15:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets. |
